Suppr超能文献

弥漫性大B细胞淋巴瘤中滤泡中心细胞肿瘤形成的免疫表型和基因标记物。

Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas.

作者信息

King B E, Chen C, Locker J, Kant J, Okuyama K, Falini B, Swerdlow S H

机构信息

Department of Pathology, University of Pittsburgh School of Medicine, USA.

出版信息

Mod Pathol. 2000 Nov;13(11):1219-31. doi: 10.1038/modpathol.3880226.

Abstract

Diffuse large B-cell lymphomas (DLBCL) are a biologically and clinically heterogeneous entity. Although some DLBCL represent transformation of follicular lymphomas (FL), the proportion that is of follicular center cell (FCC) origin remains uncertain. Immunophenotypic and genotypic markers used to suggest a FCC origin for a lymphoma (bcl-6 and CD10 expression, lack of CD138 expression, bcl-2 rearrangements [R]) or to subdivide DLBCL (bcl-2 expression, bcl-6 R) were therefore investigated in 22 FL and 44 DLBCL using paraffin section immunostains and Southern blot/polymerase chain reaction analysis. All FL tested were bcl-6+ (19) and CD138- (22) with 16/19 also bcl-2 and CD10+ (classic phenotype), one bcl2+, CD10- (grade III) and two bcl2-, CD10+ (grade II or III). Bcl-2R was identified in 4/5 FL-GrI, 3/6 FL-GrII, and 1/3 FL-GrIII. Bcl-6R was found in 0/5, 2/4, and 0/3 FL, respectively. All but 3/41 DLBCL were bcl-6+ with 17/37 also bcl-2+ and CD10+. Three of these cases were also CD138+. Twelve bcl-6+ cases were bcl-2+, CD10-, six bcl-2-, CD10+, and two bcl-2-, CD10-. The three bcl-6- cases were bcl-2+, CD138- and two were CD10+. Bcl-2R was identified in 5/27 DLBCL with 4/5 bcl-2+, 3/4 tested CD10+ and 4/4 bcl-6+. Bcl-6R was identified in 7/26 including three with a classic FL phenotype. The vast majority of DLBCL in this study have an immunophenotype that supports a FCC origin. Although the proportion of DLBCL that co-expressed bcl-6, CD10 and bcl-2 was lower than for the FL, absence of bcl-2 or CD10 may be associated with higher grade FL It is also possible that bcl-6 expression is not completely specific for a FCC origin. Only a minority of cases suggested postfollicular differentiation. Only a minority of DLBCL show bcl-2R, suggesting that many have a different molecular pathogenesis than most low-grade FL. Bcl-6R did not exclude a FCC origin.

摘要

弥漫性大B细胞淋巴瘤(DLBCL)在生物学和临床上是异质性实体。尽管一些DLBCL代表滤泡性淋巴瘤(FL)的转化,但起源于滤泡中心细胞(FCC)的比例仍不确定。因此,使用石蜡切片免疫染色和Southern印迹/聚合酶链反应分析,在22例FL和44例DLBCL中研究了用于提示淋巴瘤起源于FCC(bcl-6和CD10表达、缺乏CD138表达、bcl-2重排[R])或细分DLBCL(bcl-2表达、bcl-6 R)的免疫表型和基因型标志物。所有检测的FL均为bcl-6阳性(19例)和CD138阴性(22例),其中16/19例同时为bcl-2和CD10阳性(经典表型),1例bcl2阳性、CD10阴性(III级),2例bcl2阴性、CD10阳性(II级或III级)。在4/5的FL-GrI、3/6的FL-GrII和1/3的FL-GrIII中鉴定出bcl-2R。分别在0/5、2/4和0/3的FL中发现bcl-6R。除3/41例DLBCL外,其余均为bcl-6阳性,其中17/37例同时为bcl-2阳性和CD10阳性。这些病例中有3例也为CD138阳性。12例bcl-6阳性病例为bcl-2阳性、CD10阴性,6例bcl-2阴性、CD10阳性,2例bcl-2阴性、CD10阴性。3例bcl-6阴性病例为bcl-2阳性、CD138阴性,2例为CD10阳性。在5/27例DLBCL中鉴定出bcl-2R,其中4/5例bcl-2阳性,3/4检测为CD10阳性,4/4例bcl-6阳性。在7/26例中鉴定出bcl-6R,其中3例具有经典FL表型。本研究中绝大多数DLBCL的免疫表型支持起源于FCC。尽管DLBCL中同时表达bcl-6、CD10和bcl-2的比例低于FL,但缺乏bcl-2或CD10可能与高级别FL相关。也有可能bcl-6表达并非完全特异性地提示起源于FCC。只有少数病例提示滤泡后分化。只有少数DLBCL显示bcl-2R,这表明许多DLBCL的分子发病机制与大多数低级别FL不同。bcl-6R并不排除起源于FCC。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验